The Lancet Commission on prostate cancer: planning for the surge in cases

The Lancet Commission on prostate cancer: planning for the surge in cases

April 4, 2024 | Nicholas D James, Ian Tannock, James N'Dow, Felix Feng, Silke Gillessen, Syed Adnan Ali, Blanca Trujillo, Bissan Al-Lazikani, Gerhardt Attard, Freddie Bray, Eva Comperat, Ros Eeles, Omolara Fatiregun, Emily Grist, Susan Halab, Aine Haran, Daniel Herchenhorn, Michael Hofman, Mohamed Jalloh, Stacy Loeb, Archie MacNaair, Brandon Mahal, Larissa Mendes, Masood Moghul, Caroline Moore, Alicia Morgans, Michael Morris, Declan Murphy, Vedang Murthy, Paul L Nguyen, Anwar Padhani, Charles Parker, Hannah Rush, Mark Sculpher, Howard Soule, Matthew R Sydes, Derya Tilki, Nina Tunariu, Paul Villanti, Li-Ping Xie
The Lancet Commission on Prostate Cancer provides a comprehensive overview of the global burden of prostate cancer and projects that the number of new cases will increase from 1.4 million in 2020 to 2.9 million in 2040. This surge is driven by demographic changes, particularly in low-income and middle-income countries (LMICs), where late diagnosis is prevalent. The Commission emphasizes the need for urgent interventions, including early diagnosis systems, to shift the case mix from advanced to earlier-stage disease. It highlights the importance of integrating artificial intelligence and novel personnel in diagnostic pathways and the need for affordable and effective treatments. The report also discusses the challenges in LMICs, such as a shortage of specialist surgeons and radiotherapy equipment, and the need for better access to care. The Commission makes recommendations for policy, clinical practice, and research to address these issues, emphasizing the importance of early detection and improved management to reduce harm and improve outcomes.The Lancet Commission on Prostate Cancer provides a comprehensive overview of the global burden of prostate cancer and projects that the number of new cases will increase from 1.4 million in 2020 to 2.9 million in 2040. This surge is driven by demographic changes, particularly in low-income and middle-income countries (LMICs), where late diagnosis is prevalent. The Commission emphasizes the need for urgent interventions, including early diagnosis systems, to shift the case mix from advanced to earlier-stage disease. It highlights the importance of integrating artificial intelligence and novel personnel in diagnostic pathways and the need for affordable and effective treatments. The report also discusses the challenges in LMICs, such as a shortage of specialist surgeons and radiotherapy equipment, and the need for better access to care. The Commission makes recommendations for policy, clinical practice, and research to address these issues, emphasizing the importance of early detection and improved management to reduce harm and improve outcomes.
Reach us at info@study.space
[slides] The Lancet Commission on prostate cancer%3A planning for the surge in cases | StudySpace